Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 10, 2026

Fortuna Submits Exploitation Permit Application for the Diamba Sud Gold Project, Senegal

View original at globenewswire.com
Fortuna Submits Exploitation Permit Application for the Diamba Sud Gold Project, Senegal VANCOUVER, British Columbia, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Fortuna Mining Corp…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Company continues to advance early works and engineering at Diamba Sud, including site preparation activities and detailed engineering programs designed to de-risk critical path activities and support the feasibility study

    80% confidence
  • The updated Mineral Resource estimate will form the basis for the estimation of Mineral Reserves to be used in the feasibility study and will support the evaluation of a potential construction decision targeted for mid-2026

    80% confidence
  • Fortuna plans to publish an updated Mineral Resource estimate for Diamba Sud by the end of the month

    80% confidence
  • We produce gold and silver while creating long-term shared value through efficient production, environmental stewardship, and social responsibility

    80% confidence
  • Robust project economics were demonstrated in the Preliminary Economic Assessment completed in October 2025

    80% confidence
  • Sustainability is at the core of our operations and stakeholder relationships

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com